Purdue Pharma Lp Drug Patent Portfolio
Purdue Pharma Lp owns 8 orange book drugs protected by 128 US patents with Chirocaine having the least patent protection, holding only 1 patent. And Hysingla Er with maximum patent protection, holding 42 patents. Given below is the complete list of Purdue Pharma Lp's drugs and the patents protecting them.
1. Adhansia Xr
Adhansia Xr is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10722473 | Methods and compositions particularly for treatment of attention deficit disorder |
19 Nov, 2038
(14 years from now)
| Active |
| US10111839 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
| US10292938 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
| US10292939 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
| US10449159 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
| US10500162 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
| US10507186 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
| US10512612 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
| US10512613 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
| US10568841 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
| US10688060 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
| US9974752 | Methods and compositions particularly for treatment of attention deficit disorder |
30 Oct, 2035
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adhansia Xr's drug page
2. Butrans
Butrans is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9642850 | Method of providing sustained analgesia with buprenorphine |
29 Sep, 2017
(6 years ago)
| Expired |
| USRE41408 | Method of providing sustained analgesia with buprenorpine |
29 Sep, 2017
(6 years ago)
| Expired |
| USRE41489 | Method of providing sustained analgesia with buprenorphine |
29 Sep, 2017
(6 years ago)
| Expired |
| USRE41571 | Method of providing sustained analgesia with buprenorphine |
29 Sep, 2017
(6 years ago)
| Expired |
| US6264980 | Transdermal resorption of active substances from supercooled masses of levulic acid |
18 Dec, 2015
(8 years ago)
| Expired |
| US6344211 | Transdermal absorption of active substances from subcooled melts |
18 Dec, 2015
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Butrans's drug page
3. Chirocaine
Chirocaine is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5708011 | Use of levobupivacaine in a patient having depressed myocardial contractility |
13 Oct, 2014
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Chirocaine's drug page
4. Hysingla Er
Hysingla Er is protected by 42 patents, out of which 22 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8808740 | Encased tamper resistant controlled release dosage forms |
21 Dec, 2031
(7 years from now)
| Active |
| US9572779 | Encased tamper resistant controlled release dosage forms |
21 Dec, 2031
(7 years from now)
| Active |
| US9750703 | Encased tamper resistant controlled release dosage forms |
21 Dec, 2031
(7 years from now)
| Active |
| US9861584 | Tamper resistant controlled release dosage forms |
21 Dec, 2031
(7 years from now)
| Active |
| US9872837 | Tamper resistant controlled release dosage forms |
21 Dec, 2031
(7 years from now)
| Active |
| US11304908 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US11304909 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9084816 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9095614 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9095615 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9486412 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9486413 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9492389 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9492390 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9492391 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9545380 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9763933 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9770416 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9775809 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US11844865 | Abuse-proofed oral dosage form |
13 Feb, 2025
(4 months from now)
| Active |
| US10130591 | Abuse-proofed dosage form |
20 Nov, 2023
(9 months ago)
| Expired |
| US8309060 | Abuse-proofed dosage form |
20 Nov, 2023
(9 months ago)
| Expired |
| US10369109 | Abuse-proofed dosage form |
16 Jun, 2023
(1 year, 3 months ago)
| Expired |
| US9675610 | Abuse-proofed dosage form |
16 Jun, 2023
(1 year, 3 months ago)
| Expired |
| US8529948 | Pharmaceutical formulation containing gelling agent |
06 Aug, 2022
(2 years ago)
| Expired |
| US6733783 | Controlled release hydrocodone formulations |
30 Oct, 2021
(2 years ago)
| Expired |
| US8361499 | Controlled release hydrocodone formulations |
30 Oct, 2021
(2 years ago)
| Expired |
| US8551520 | Controlled release hydrocodone |
30 Oct, 2021
(2 years ago)
| Expired |
| US8647667 | Controlled release hydrocodone formulations |
30 Oct, 2021
(2 years ago)
| Expired |
| US9023401 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
| US9056052 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
| US9060940 | Controlled release hydrocodone |
30 Oct, 2020
(3 years ago)
| Expired |
| US9198863 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
| US9205056 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
| US9289391 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
| US9517236 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
| US9572804 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
| US9669023 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
| US9669024 | Controlled release hydrocodone formulations |
30 Oct, 2020
(3 years ago)
| Expired |
| US9675611 | Methods of providing analgesia |
30 Oct, 2020
(3 years ago)
| Expired |
| US9682077 | Methods of providing analgesia |
30 Oct, 2020
(3 years ago)
| Expired |
| US6488963 | Hot-melt extrudable pharmaceutical formulation |
24 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hysingla Er's drug page
5. Oxycontin
Oxycontin is protected by 32 patents, out of which 9 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8894987 | Tamper resistant dosage forms |
29 Mar, 2030
(5 years from now)
| Active |
| US11304908 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US11304909 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US11964056 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US8808741 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US8894988 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9492389 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9492391 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9492392 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9492393 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9763933 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9770416 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US9775808 | Tamper resistant dosage forms |
24 Aug, 2027
(2 years from now)
| Active |
| US7776314 | Abuse-proofed dosage system |
19 Apr, 2025
(6 months from now)
| Active |
| US10407434 | Process for preparing oxycodone compositions |
30 Mar, 2025
(6 months from now)
| Active |
| US10696684 | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(6 months from now)
| Active |
| US12060361 | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(6 months from now)
| Active |
| US7674799 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(6 months from now)
| Active |
| US7674800 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(6 months from now)
| Active |
| US7683072 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(6 months from now)
| Active |
| US9073933 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(6 months from now)
| Active |
| US9522919 | Oxycodone compositions |
30 Mar, 2025
(6 months from now)
| Active |
| US8114383 | Abuse-proofed dosage form |
10 Oct, 2024
(20 days from now)
| Active |
| US10130591 | Abuse-proofed dosage form |
20 Nov, 2023
(9 months ago)
| Expired |
| US10675278 | Crush resistant delayed-release dosage forms |
20 Nov, 2023
(9 months ago)
| Expired |
| US8309060 | Abuse-proofed dosage form |
20 Nov, 2023
(9 months ago)
| Expired |
| US10369109 | Abuse-proofed dosage form |
16 Jun, 2023
(1 year, 3 months ago)
| Expired |
| US9675610 | Abuse-proofed dosage form |
16 Jun, 2023
(1 year, 3 months ago)
| Expired |
| US8337888 | Pharmaceutical formulation containing gelling agent |
06 Aug, 2022
(2 years ago)
| Expired |
| US9060976 | Pharmaceutical formulation containing gelling agent |
06 Aug, 2022
(2 years ago)
| Expired |
| US6488963 | Hot-melt extrudable pharmaceutical formulation |
24 Jun, 2017
(7 years ago)
| Expired |
| US5508042 | Controlled release oxycodone compositions |
16 Apr, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oxycontin's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Palladone
Palladone is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6589960 | Hydromorphone and hydrocodone compositions and methods for their synthesis |
09 Nov, 2020
(3 years ago)
| Expired |
| US5958452 | Extruded orally administrable opioid formulations |
04 Nov, 2014
(9 years ago)
| Expired |
| US5965161 | Extruded multi-particulates |
04 Nov, 2014
(9 years ago)
| Expired |
| US6335033 | Melt-extrusion multiparticulates |
04 Nov, 2014
(9 years ago)
| Expired |
| US6706281 | Melt-extrusion multiparticulates |
04 Nov, 2014
(9 years ago)
| Expired |
| US6743442 | Melt-extruded orally administrable opioid formulations |
04 Nov, 2014
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Palladone's drug page
7. Targiniq
Targiniq is protected by 24 patents, out of which 19 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7674799 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(6 months from now)
| Active |
| US7674800 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(6 months from now)
| Active |
| US7683072 | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
30 Mar, 2025
(6 months from now)
| Active |
| US9073933 | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
30 Mar, 2025
(6 months from now)
| Active |
| US9522919 | Oxycodone compositions |
30 Mar, 2025
(6 months from now)
| Active |
| US8846090 | Matrix for sustained, invariant and independent release of active compounds |
04 Apr, 2023
(1 year, 5 months ago)
| Expired |
| US8846091 | Matrix for sustained, invariant and independent release of active compounds |
04 Apr, 2023
(1 year, 5 months ago)
| Expired |
| US9555000 | Pharmaceutical preparation containing oxycodone and naloxone |
04 Apr, 2023
(1 year, 5 months ago)
| Expired |
| US9907793 | Pharmaceutical preparation containing oxycodone and naloxone |
04 Apr, 2023
(1 year, 5 months ago)
| Expired |
| US8969369 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
| US9056051 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
| US9084729 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
| US9161937 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
| US9168252 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
| US9283216 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
| US9283221 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
| US9345701 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
| US9511066 | Abuse-resistant controlled-release opioid dosage form |
10 May, 2022
(2 years ago)
| Expired |
| US6277384 | Opioid agonist/antagonist combinations |
22 Dec, 2018
(5 years ago)
| Expired |
| US6696066 | Opioid agonist/antagonist combinations |
22 Dec, 2018
(5 years ago)
| Expired |
| US8673355 | Opioid agonist/antagonist combinations |
22 Dec, 2018
(5 years ago)
| Expired |
| US8822487 | Opioid agonist/opioid antagonist/acetaminophen combinations |
22 Dec, 2018
(5 years ago)
| Expired |
| US9205082 | Opioid agonist/antagonist combinations |
22 Dec, 2018
(5 years ago)
| Expired |
| US9474750 | Opioid agonist/opioid antagonist/acetaminophen combinations |
22 Dec, 2018
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Targiniq's drug page
8. Zurnai (autoinjector)
Zurnai (autoinjector) is protected by 21 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11857547 | Compositions and methods for opioid antagonist delivery |
05 Nov, 2039
(15 years from now)
| Active |
| US11865112 | Compositions and methods for opioid antagonist delivery |
05 Nov, 2039
(15 years from now)
| Active |
| US11191908 | Syringe shock absorber for use in an injection device |
18 Oct, 2035
(11 years from now)
| Active |
| US11813435 | Needle assisted injection device having reduced trigger force |
25 Feb, 2035
(10 years from now)
| Active |
| US10881798 | Needle assisted injection device having reduced trigger force |
11 Feb, 2034
(9 years from now)
| Active |
| US11185642 | Injection device with cammed ram assembly |
28 Aug, 2031
(6 years from now)
| Active |
| US10357609 | Needle assisted jet injection device having reduced trigger force |
21 Aug, 2031
(6 years from now)
| Active |
| US10905827 | Injection device with cammed ram assembly |
21 Aug, 2031
(6 years from now)
| Active |
| US11446440 | Needle assisted injection device having reduced trigger force |
21 Aug, 2031
(6 years from now)
| Active |
| US8496619 | Injection device with cammed ram assembly |
21 Aug, 2031
(6 years from now)
| Active |
| US9364610 | Injection device with cammed ram assembly |
21 Aug, 2031
(6 years from now)
| Active |
| US9364611 | Needle assisted jet injection device having reduced trigger force |
21 Aug, 2031
(6 years from now)
| Active |
| US9446195 | Injection device with cammed ram assembly |
21 Aug, 2031
(6 years from now)
| Active |
| US10279131 | Injection device with cammed RAM assembly |
31 Jul, 2031
(6 years from now)
| Active |
| US8021335 | Prefilled syringe jet injector |
04 Oct, 2026
(2 years from now)
| Active |
| US10478560 | Prefilled syringe injector |
24 Jan, 2026
(1 year, 4 months from now)
| Active |
| US11446441 | Prefilled syringe injector |
24 Jan, 2026
(1 year, 4 months from now)
| Active |
| US8562564 | Prefilled syringe jet injector |
24 Jan, 2026
(1 year, 4 months from now)
| Active |
| US9180259 | Prefilled syringe jet injector |
24 Jan, 2026
(1 year, 4 months from now)
| Active |
| US9533102 | Prefilled syringe jet injector |
24 Jan, 2026
(1 year, 4 months from now)
| Active |
| US9629959 | Prefilled syringe jet injector |
24 Jan, 2026
(1 year, 4 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zurnai (autoinjector)'s drug page